Skip to main
KOD

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences is a biopharmaceutical company with a promising pipeline of retinal medicines built on its proprietary Antibody Biopolymer Conjugate (ABC) platform. The company recently reported strong results in its GLOW2 study for tarcocimab tedromer (Zenkuda) in patients with non-proliferative diabetic retinopathy, supporting its multi-indication BLA filing. The company's other investigational medicines, KSI-501 and KSI-101, also show potential in treating retinal vascular diseases and have upcoming pivotal data readouts. While there are risks to the achievement of the target price, including competition and platform risks, we maintain a positive outlook on Kodiak Sciences based on its innovative platform and potential for strong financial performance in the future.

Bears say

Kodiak Sciences is currently facing a number of potential risks, including delays in regulatory approvals, competition from other innovative products in development, and the need for additional funding. Despite the positive Phase 3 GLOW2 results and potential for their ABC platform to address current anti-VEGF limitations, the company's outlook may be hindered by binary risks surrounding future datasets and the possibility for delays or setbacks in development. Additionally, there is a growing market for retinal medicine with emerging competition, which may impact Kodiak's potential for long-term profitability.

KOD has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 7 analysts, KOD has a Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.